Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Manuscript
  • Published:

Therapy

Randomized comparison of interferon α and hydroxyurea with hydroxyurea monotherapy in chronic myeloid leukemia (CML-study II): prolongation of survival by the combination of interferon α and hydroxyurea

Abstract

The optimum treatment conditions of interferon (IFN) α therapy in chronic myeloid leukemia (CML) are still controversial. To evaluate the role of hydroxyurea (HU) for the outcome of IFN therapy, we conducted a randomized trial to compare the combination of IFN and HU vs HU monotherapy (CML-study II). From February 1991 to December 1994, 376 patients with newly diagnosed CML in chronic phase were randomized. In all, 340 patients were Ph/BCR-ABL positive and evaluable. Randomization was unbalanced 1:2 in favor of the combination therapy, since study conditions were identical to the previous CML-study I and it had been planned in advance to add the HU patients of study I (n=194) to the HU control group. Therefore, a total of 534 patients were evaluable (226 patients with IFN/HU and 308 patients with HU). Analyses were according to intention-to-treat. Median observation time of nontransplanted living patients was 7.6 years (7.9 years for IFN/HU and 7.3 years for HU). The risk profile (new CML score) was available for 532 patients: 200 patients (38%) were low, 239 patients (45%) intermediate, and 93 patients (17%) high risk. Complete hematologic response rates were higher in IFN/HU-treated patients (59 vs 32%). Of 169 evaluable IFN/HU-treated patients (75%), 104 patients (62%) achieved a cytogenetic response that was complete in 12% (n=21), major in 14% (n=24), and at least minimal in 35% (n=59). Of the 534 patients, 105 (20%) underwent allogeneic stem cell transplantation in first chronic phase. In the low-risk group, 65 of 200 patients were transplanted (33%), 30 (13%) in the intermediate-risk group, and nine (10%) in the high-risk group. Duration of chronic phase was 55 months for IFN/HU and 41 months for HU (P<0.0001). Median survival was 64 months for IFN/HU and 53 months for HU-treated patients (P=0.0063). We conclude that IFN in combination with HU achieves a significant long-term survival advantage over HU monotherapy. In view of the data of CML-study I, these results suggest that IFN/HU is also superior to IFN alone. HU should be combined with IFN in IFN-based therapies and for comparisons with new therapies.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7
Figure 8

Similar content being viewed by others

References

  1. Chronic Myeloid Leukemia Trialist's Collaborative Group. Interferon alfa versus chemotherapy for chronic myeloid leukemia: a meta-analysis of seven randomized trials. J Natl Cancer Inst 1997; 89: 1616–1620.

  2. Hehlmann R, Heimpel H, Hasford J, Kolb HJ, Pralle H, Hossfeld DK et al. Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia. Blood 1994; 84: 4064–4077.

    CAS  Google Scholar 

  3. The Italian Cooperative Study Group on Chronic Myeloid Leukemia. Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. N Engl J Med 1994; 330: 820–825.

  4. Chronic Myeloid Leukemia Trialists' Collaborative Group. Hydroxyurea versus busulphan for chronic myeloid leukaemia: an individual patient data meta-analysis of three randomized trials. Br J Haematol 2000; 110: 573–576.

  5. Silver RT, Woolf SH, Hehlmann R, Appelbaum FA, Anderson J, Bennett C et al. Review: an evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American Society of Hematology. Blood 1999; 94: 1517–1536.

    CAS  Google Scholar 

  6. Bonifazi F, De Vivo A, Rosti G, Guilhot F, Guilhot J, Trabacchi E et al. Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders. Blood 2001; 98: 3074–3081.

    Article  CAS  Google Scholar 

  7. The Italian Cooperative Study Group on Chronic Myeloid Leukemia. Long-term follow-up of the Italian trial of interferon-α versus conventional chemotherapy in chronic myeloid leukemia. Blood 1998; 92: 1541–1548.

  8. Kantarjian HM, Smith TL, O'Brien S, Beran M, Pierce S, Talpaz M et al. Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-α therapy. Ann Intern Med 1995; 122: 254–261.

    Article  CAS  Google Scholar 

  9. O'Brien S, Guilhot F, Larson R, Gathmann I, Baccarani M, Cervantes F et al. The IRIS study: International randomized study of interferon and low-dose ara-C versus STI571 (imatinib) in patients with newly-diagnosed chronic phase chronic myeloid leukemia. N Engl J Med 2003; 348: 994–1004.

    Article  CAS  Google Scholar 

  10. Kantarjian HM, Cortes JE, O'Brien S, Giles F, Garcia-Manero G, Faderl S et al. Imatinib mesylate therapy in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia: high incidence of early complete and major cytogenetic responses. Blood 2003; 101: 97–100.

    Article  CAS  Google Scholar 

  11. Hehlmann R, Heimpel H, Hossfeld DK, Hasford J, Kolb HJ, Löffler H et al. Randomized study of the combination of hydroxyurea and interferon alpha versus hydroxyurea monotherapy during the chronic phase of chronic myelogenous leukemia (CML Study II). Bone Marrow Transplant 1996; 17 (Supp 3): S21–S24.

    PubMed  Google Scholar 

  12. Hehlmann R, Hochhaus A, Kolb HJ, Hasford J, Gratwohl A, Heimpel H et al. Interferon α before allogeneic bone marrow transplantation in chronic myelogenous leukemia does not affect outcome adversely provided it is discontinued at least 90 days before the procedure. Blood 1999; 94: 3668–3677.

    CAS  Google Scholar 

  13. Hehlmann R, Heimpel H, Hasford J, Kolb HJ, Pralle H, Hossfeld DK et al. Randomized comparison of busulfan and hydroxyurea in chronic myelogenous leukemia: Prolongation of survival by hydroxyurea. Blood 1993; 82: 398–407.

    CAS  PubMed  Google Scholar 

  14. Anger B, Porzsolt F, Leichtle R, Heinze B, Bartram C, Heimpel H . A phase I/II study of recombinant interferon alpha 2a and hydroxyurea for chronic myelocytic leukemia. Blut 1989; 58: 275–278.

    Article  CAS  Google Scholar 

  15. Hasford J, Pfirrmann M, Hehlmann R, Allan NC, Baccarani M, Kluin-Nelemans J et al. A new prognostic score for the survival of patients with chronic myeloid leukemia treated with interferon alfa. J Natl Cancer Inst 1998; 90: 850–858.

    Article  CAS  Google Scholar 

  16. Reiter A, Skladny H, Hochhaus A, Seifarth W, Heimpel H, Bartram CR et al. Molecular response of CML patients treated with interferon alpha monitored by quantitative Southern blot analysis. Br J Haematol 1997; 97: 86–93.

    Article  CAS  Google Scholar 

  17. Cross NCP, Melo JV, Feng L, Goldman JM . An optimized multiplex polymerase chain reaction (PCR) for detection of BCR-ABL fusion mRNAs in haematological disorders. Leukemia 1994; 8: 186–189.

    CAS  Google Scholar 

  18. Hochhaus A, Lin F, Reiter A, Skladny H, Mason PJ, van Rhee F et al. Quantification of residual disease in chronic myelogenous leukemia patients on interferon-α therapy by competitive polymerase chain reaction. Blood 1996; 87: 1549–1555.

    CAS  Google Scholar 

  19. George SL, Desu MM . Planning of size and duration of a clinical trial studying the time to some critical event. J Chronic Dis 1974; 27: 15–24.

    Article  CAS  Google Scholar 

  20. O'Brien PC, Fleming TR . Multiple testing procedure for clinical trials. Biometrics 1979; 35: 549–556.

    Article  CAS  Google Scholar 

  21. Harris EK, Albert A . Survivorship Analysis for Clinical Studies. New York: Marcel Dekker, 1991.

    Google Scholar 

  22. Mantel N, Byar DP . Evaluation of response-time data involving transient states: an illustration using heart-transplant data. J Am Stat Assoc 1974; 69: 81–86.

    Article  Google Scholar 

  23. Simon R, Makuch RW . A non-parametric graphical representation of the relationship between survival and the occurence of an event: application to responder versus non-responder bias. Stat Med 1984; 3: 35–44.

    Article  CAS  Google Scholar 

  24. Guilhot F, Chastang C, Michallet M, Guerci A, Harousseau JL, Maloisel F et al. Interferon alpha2b (IFN) combined with cytarabine versus interferon alone in chronic myelogenous leukemia. N Engl J Med 1997; 337: 223–229.

    Article  CAS  Google Scholar 

  25. Giles FJ, Shan J, Chen S, Advani SH, Supandiman I, Aziz Z et al. A prospective randomized study of alpha-2b interferon plus hydroxyurea or cytarabine for patients with early chronic phase chronic myelogenous leukemia: the International Oncology Study Group CML1 study. Leukemia Lymphoma 2000; 37: 367–377.

    Article  CAS  Google Scholar 

  26. Baccarani M, Rosti G, De Vivo A, Bonifazi F, Russo D, Martinelli G et al. A randomized study of interferon-alpha versus interferon-alpha and low-dose arabinosyl cytosine in chronic myeloid leukemia. Blood 2002; 99: 1527–1535.

    Article  CAS  Google Scholar 

  27. The Benelux CML Study Group. Randomized study on hydroxyurea alone versus hydroxyurea combined with low-dose interferon-α2b for chronic myeloid leukemia. Blood 1998; 91: 2713–2721.

  28. Allan NC, Richards SM, Shepherd PC . UK Medical Research Council randomised, multicentre trial of interferon- alpha n1 for chronic myeloid leukaemia: improved survival irrespective of cytogenetic response. The UK Medical Research Council's Working Parties for Therapeutic Trials in Adult Leukaemia. Lancet 1995; 345: 1392–1397.

    Article  CAS  Google Scholar 

  29. Mahon FX, Montastruc M, Faberes C, Reiffers J . Predicting complete cytogenetic response in chronic myelogenous leukemia patients treated with recombinant interferon α. Blood 1994; 84: 3592–3594.

    CAS  PubMed  Google Scholar 

  30. Hasford J, Pfirrmann M, Hehlmann R, Baccarani M, Guilhot F, Mahon FX et al. Prognosis and prognostic factors for patients with chronic myeloid leukemia: nontransplant therapy. Semin Hematol 2003; 40: 4–12.

    Article  CAS  Google Scholar 

  31. Shepherd P, Kluin-Nelemans H, Richards S, Le Cessie S, on behalf of the MRC Adult Leukaemia Working Party and the HOVON 20 CML Group. A randomised comparison of low or high dose IFN-alpha in newly diagnosed CML patients shows no difference in major cytogenetic response rate or survival between the two groups — results of MRC CML V & HOVON 20 trials. Blood. 2001; 98: 727a.

    Article  Google Scholar 

Download references

Acknowledgements

The assistance of M Dumke, C Folz, G Lalla, K Adam, and K Enghofer is greatfully acknowledged. This study was supported by the Süddeutsche Hämoblastosegruppe (SHG) through a grant of Hoffmann-La Roche to SHG and by the Forschungsfond of the Fakultät für Klinische Medizin Mannheim, University of Heidelberg.

Participating institutions were as follows: Aachen: Hämatologisch-Onkologische Praxis (U Essers, L Habets); Aarau: Kantonsspital, Med. Klinik (K Giger, M Wernli); Aschaffenburg: Klinikum, Med. Klinik (W Fischbach, J Brücher); Augsburg: Zentralklinikum, II. Med. Klinik (G Schlimok); Bad Saarow: Humaine Klinikum, Klinik f. Innere Medizin (W Schultze); Basel: Kantonsspital, Hämatologie/Onkologie (A Gratwohl, A Tichelli); Bayreuth: Krankenhaus Hohe Warte, Med. Klinik (D Seybold) Berlin: Hämatologische Praxis (BR Suchy); Krankenhaus Moabit, II. Innere Abteilung (K-P Hellriegel); Krankenhaus Berlin-Neukölln, II. Innere Abteilung (AC Mayr, G Middelhoff, A Grüneisen); II. Kinderklinik Berlin-Buch, (W Dörffel); Hämatologisch-Onkologische Schwerpunktpraxis (I Blau); Bern: Universitätsklinik, (A Tobler); Bonn: Universitätspoliklinik (H Vetter, YD Ko); Bremen: Zentralkrankenhaus (H Rasche, CR Meier); Duisburg: St-Johannes-Hospital, Med. Klinik II (M Westerhausen, W Fett, C Aul); Emden: Hans-Susemihl-Krankenhaus Med. Klinik I (F Lindemann, H Becker); Erfurt: Hämatologische Praxis (J Weniger); Erfurt: Klinikum, Med. Klinik (K Wutke, D Küstner); Internistische Praxis (U Hauch); Fürth: II. Med. Klinik (J Fink); Göppingen; Klinik am Eichert, Med. Klinik II (E Kurrle, T Schmeiser); Gießen: Medizinische Klinik V, Zentrum für Innere Medizin (H Pralle); Hagen: Kath. Krankenhaus, Hämatologie/Onkologie (H Eimermacher); Hamburg: Universitätsklinik, Hamburg-Eppendorf (DK Hossfeld, U Dührsen); Hämatologisch-Onkologische Praxis (UR Kleeberg); Allgemeines Krankenhaus Barmbek (U Müllerleile); Allgemeines Krankenhaus Altona, II. Med. Abt. (K Mainzer, Dr Meyran); Allgem. Krankenhaus St Georg (R Kuse, C zur Verth); Internistische Praxis (A Mohr); Herford: Kreiskrankenhaus, Med. Klinik II (U Schmitz-Huebner); Hannover: Pathologisches Institut und Institut f. Klinische Immunologie der MHH (A Georgii, T Buhr); Institut f. Klinische Immunologie der MHH (H Deicher, P von Wussow); Kaiserslautern: Westpfalz-Klinikum (H Kreiter); Karlsruhe: Städt. Klinikum, II. Med. Klinik (JTh Fischer); Kempten: Klinikum Kempten-Oberallgäu, Innere Abteilung (V Hiemeyer); Kiel: Städt. Krankenhaus (H Löffler); Universitätsklinik (HD Bruhn); Köln I. Med. Universitätsklinik (V Diehl, C Scheid); Praxisgemeinschaft (R Zankovich); Lebach: Caritas-Krankenhaus (D Hufnagl, S Kremers) Lemgo: Klinikum Lippe/Lemgo (H-P Lohrmann); Lindenfels: Luisenkrankenhaus (J Hesselmann); Ludwigshafen: St Marienkrankenhaus, Med. Klinik (H Weiss, A Seifert); Lüneburg: Gemeinschaftspraxis (B Goldmann); Mannheim: Universitätsklinikum, III. Med. Klinik (R Hehlmann, U Berger, A Hochhaus, A Reiter, G Metzgeroth, O Maywald, W Queißer); München: Universitätsklinikum Großhadern (H-J Kolb, A Muth); Universitätsklinikum Innenstadt (B Emmerich, M Hallek); Krankenhaus München-Schwabing (C Nerl, W Kaboth); Städt. Krankenhaus München-Harlaching (R Hartenstein, N Brack); Klinikum r. d. Isar d. TU (J Rastetter, M Perker); Institut für Med. Informationsverarbeitung, Statistik und Biomathematik der LMU und Biometrisches Zentrum für Therapiestudien (K Überla, J Hasford, H Ansari, M Pfirrmann); Münster: Universitätsklinik, Kinderheilkunde (B Rath); Neuruppin: Ruppiner Klinikum, Med. Klinik B, (H Eggebrecht, D Nürnberg); Nürnberg: VII Medizinische Klinik (W Brockhaus), V Medizinische Klinik (WM Gallmeier, C Falge); Oberhausen: Gemeinschaftspraxis (A Brunöhler); Oldenburg: Städt. Kliniken, Innere Medizin (F del Valle); Penzberg: Städt. Krankenhaus (K Ranft); Ravensburg: St Elisabeth-Krankenhaus Med. Klinik (G Meuret, S Mende); Regensburg: Krankenhaus der Barmherzigen Brüder (W Wellens, J Weiß, M Schenk); Schwäbisch-Hall: Diakonie-Krankenhaus (HH Heißmeyer, T Geer); St Gallen: Kantonsspital, Onkologische Abteilung (T Cerny, U Hess); Traunstein: Klinikum Traunstein, Onkologische Abteilung (H-G Biedermann); Ulm: Universitätsklinik, Med. Klinik III (H Heimpel, M Griesshammer); Institut f. Arbeits-und Sozialmedizin und Abteilung f. Humangenetik (B Heinze, TM Fliedner, W Vogel) Waldbröl: Kreiskrankenhaus, Med. Klinik (L Labedzki); Wiesbaden: Dr-Horst-Schmidt-Kliniken GmbH (N Frickhofen, H-G Fuhr); Wilhelmshaven: St Willehad-Hospital (W Augener); Würzburg: Universitätsklinik, Med. Poliklinik (K Wilms, M Wilhelm, H Rückle-Lanz).

Author information

Authors and Affiliations

Authors

Consortia

Additional information

One might wonder whether there is still place for the publication of studies like these given the imatinib enthusiasm. Yet, this study is certainly important because it gives mature and solid long-term data of standard therapy IFN- or chemotherapy based that can serve as comparative controls for future studies with newer drugs such as imatinib

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hehlmann, R., Berger, U., Pfirrmann, M. et al. Randomized comparison of interferon α and hydroxyurea with hydroxyurea monotherapy in chronic myeloid leukemia (CML-study II): prolongation of survival by the combination of interferon α and hydroxyurea. Leukemia 17, 1529–1537 (2003). https://doi.org/10.1038/sj.leu.2403006

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2403006

Keywords

This article is cited by

Search

Quick links